THE BLIND SPOT IN DRUG PREVENTION: WHAT DO EXISTING INDICATORS FAIL TO CAPTURE?
Emerging Synthetic Substances, Information Gaps and the Need for More Effective Prevention
The illicit drug market is changing, but are our prevention systems changing at the same pace?
Arrests, drug seizures, hospital admissions, and overdose statistics provide important information about the scale and consequences of drug-related harm. However, these indicators largely describe events that have already occurred.
They do not necessarily indicate how quickly new substances enter the market, how effectively emerging threats are identified, or whether prevention efforts prepare communities for risks that have not yet become widely visible.
This distinction matters.
The emergence of new synthetic opioids, changing drug compositions, and the appearance of non-opioid substances in illicit drug mixtures create challenges that cannot be addressed through traditional prevention messages alone.
The question is not simply whether we are collecting information.
It is whether we are collecting the right information, interpreting it correctly, and translating it into timely action.
1. ARE WE IDENTIFYING NEW THREATS FAST ENOUGH?
One of the major challenges in monitoring the illicit drug market is the continuous emergence of new psychoactive substances and changing combinations of known substances.
Nitazenes, a group of highly potent synthetic opioids, have raised particular concern because of their toxicity and the challenges associated with their detection.
At the same time, substances such as xylazine and medetomidine, which are veterinary or medical sedatives rather than opioids, have been identified in some illicit drug mixtures. Their presence introduces additional health risks and complicates the response to drug-related emergencies.
Routine toxicological screening does not necessarily detect every emerging compound. Identification may require specialized analytical methods and access to updated reference information.
This raises several important questions:
• How quickly can laboratories identify substances that are not included in routine screening?
• How effectively are findings shared between forensic laboratories, public health services and law enforcement?
• How quickly can verified information reach professionals and communities that need it?
• Are existing monitoring systems sufficiently prepared to recognize changing drug compositions?
A substance that has not yet been identified cannot be adequately addressed through information that does not include it.
2. ARE WE MEASURING WHAT YOUNG PEOPLE ACTUALLY KNOW?
Prevention programmes frequently measure awareness by asking whether young people have heard about particular drugs or understand that substance use can be harmful.
However, familiarity with drug terminology does not necessarily translate into practical understanding.
A young person may recognize a substance's name but not understand the risks of counterfeit tablets, unknown mixtures, or products falsely presented as legitimate medication.
The changing market also challenges the assumption that familiar appearances or names provide reliable information about a product's contents.
Prevention education should therefore assess more than recognition and general awareness.
It should examine whether young people understand:
• Why the appearance or packaging of an illicit product cannot establish its actual contents.
• Why substances sold under familiar names may have different compositions.
• Why previous experience with a substance does not guarantee that a subsequent product will have the same effects or risks.
• How to recognize a suspected poisoning emergency and seek immediate professional assistance.
• Where to access reliable and verified information.
Educational interventions should be evaluated through knowledge assessments, practical scenarios and follow-up measurements, rather than relying exclusively on attendance or self-reported awareness.
3. ARE WE MEASURING PREVENTION OUTCOMES OR SIMPLY COUNTING ACTIVITIES?
Another important gap concerns how prevention programmes are evaluated.
The number of workshops conducted, participants reached, campaigns organized, and educational materials distributed can demonstrate the scale of programme delivery.
However, these figures alone cannot establish whether a programme has improved knowledge, strengthened decision-making, or contributed to reduced drug-related harm.
A more meaningful evaluation should distinguish between three levels:
Programme delivery: What activities were completed and who was reached?
Learning outcomes: What did participants actually understand, retain, and learn to apply?
Longer-term outcomes: Did the intervention contribute to measurable improvements in relevant protective behaviours, access to support, or other clearly defined prevention objectives?
This distinction is essential.
A completed activity is evidence that an activity took place. It is not, by itself, evidence of prevention effectiveness.
Programmes should therefore establish measurable objectives before implementation and evaluate their outcomes using appropriate methods.
4. WHAT NEEDS TO CHANGE?
Responding to emerging synthetic drug threats requires more than updating educational materials whenever a new substance becomes known.
It requires improvements in the way information is collected, evaluated, and communicated.
Several priorities deserve attention:
Strengthen early-warning and monitoring systems. Improve the capacity to identify emerging substances and communicate verified findings in a timely manner.
Improve multidisciplinary cooperation. Encourage appropriate information exchange between forensic laboratories, toxicological services, public health authorities, law enforcement, customs, and prevention professionals.
Modernize prevention education. Ensure that educational content reflects current developments in the drug market rather than relying exclusively on familiar substances and outdated examples.
Introduce meaningful evaluation. Measure knowledge acquisition, retention, and clearly defined programme outcomes, not only the number of activities delivered.
Address information gaps responsibly. Improve understanding of emerging patterns while protecting confidentiality, privacy and the rights of individuals.
These measures are not a guarantee that every emerging threat will be detected in advance. They are practical steps towards a more responsive and better-informed prevention system.
FROM REACTIVE INFORMATION TO MEANINGFUL PREVENTION
The synthetic drug market presents a continuing challenge to public health, education, law enforcement and prevention systems.
No single institution can address this challenge independently. Effective responses require reliable information, appropriate scientific capacity, professional cooperation and prevention programmes that are regularly evaluated and updated.
We should not confuse the amount of information we collect with the quality of our understanding.
Nor should we confuse the number of prevention activities with their actual impact.
The real test of prevention is not how much activity we can report, but whether our knowledge, preparedness and actions are making a measurable difference.
A QUESTION FOR THE PREVENTION COMMUNITY
If the synthetic drug market can change faster than our existing systems, what should we change first: our monitoring capacity, our prevention education, or the way we measure results?
This is not simply a question of resources. It is a question of priorities, preparedness, and institutional responsibility.


Comments
No approved comments yet. Be the first!
Log in or register to leave a comment.